Griffin P. Rodgers is the director of the National Institute of Diabetes and Digestive and Kidney Diseases, one of the 27 institutes that make up the United States National Institutes of Health. He is also the Chief of the institute's Molecular and Clinical Hematology Branch and is known for contributions to research and therapy for sickle cell anemia.[1]
Griffin Rodgers | |
|---|---|
 | |
| Education | Brown University (BS, MS, MD) Johns Hopkins University (MBA) |
| Known for | Research on sickle cell anemia |
| Awards | Mastership from the American College of Physicians (2005) |
| Scientific career | |
| Institutions | National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases |
Education
editRodgers graduated from Brown University for his undergraduate (1976), graduate (1979), and medical degrees (1979), and holds an MBA from Johns Hopkins Carey Business School (2005).[2] He is a hematologist who has been board-certified in internal medicine, emergency medicine, and hematology.[3]
NIH career
editRodgers first joined the NIH in 1984.[4] He became the Chief of the Molecular and Clinical Hematology Branch in 1998 and the NIDDK Deputy Director in 2001. In 2006, he assumed the directorship on an acting basis and this position was made permanent in 2007 by the NIH's director at the time, Elias Zerhouni.[3]
Research
editRodgers is a physician-scientist who studies diseases of bone marrow and is best known for his work on the molecular genetics of hemoglobinopathies and on developing a treatment for sickle cell anemia.[1] He was a major contributor to the development of hydroxyurea therapy,[5] which was approved by the FDA in 1998.[6]
A 2009 study, published under the mentorship of Griffin P. Rodgers, discovered that in human erythrocytes (peripheral blood CD34+ cells), the stem cell factor (SCF) induces γ-globin gene expression by regulating downstream transcription factor COUP-TFII, which can be a crucial molecular mechanism that has the potential for the development of effective pharmacologic strategies for treatment of patients with sickle cell disease or other β-hemoglobinopathies.[7] However, a 2015 study by a group from University of Michigan (Ann Arbor), was unable to replicate, and hence contradicted, the 2009 study.[8] The 2015 study concludes that "we were unable to provide evidence for COUP-TFII expression under any in vivo or in vitro culture condition from human or mouse adult erythroid cells, confirming previous microarray, as well as RNA-seq studies."[8]
Awards and memberships
editRodgers was awarded a Mastership from the American College of Physicians in 2005.[3] He received an honorary Doctor of Science degree from Washington University in St. Louis in 2011.[9]
References
edit- ^ a b "Griffin P. Rodgers, M.D., M.A.C.P." NIDDK Staff Directory. National Institutes of Health. Retrieved 15 March 2015.
- ^ "Griffin P. Rodgers, M.D., M.A.C.P. | Principal Investigators | NIH Intramural Research Program". irp.nih.gov. Retrieved 2022-12-24.
- ^ a b c "Griffin P. Rodgers, M.D., Named Director of NIH's National Institute of Diabetes and Digestive and Kidney Diseases". NIH News. National Institutes of Health. Retrieved 15 March 2015.
- ^ "NIH scientist transforming treatment of sickle cell disease". The Washington Post. Retrieved 15 March 2015.
- ^ Schechter, AN; Rodgers, GP (18 May 1995). "Sickle cell anemia--basic research reaches the clinic". The New England Journal of Medicine. 332 (20): 1372–4. doi:10.1056/nejm199505183322010. PMID 7536300.
- ^ Jodi B Segal; John J Strouse; Mary Catherine Beach; Carlton Haywood; Catherine Witkop; Haeseong Park; Renee F Wilson; Eric B Bass; Sophie Lanzkron (2008). "Introduction". Hydroxyurea for the Treatment of Sickle Cell Disease (Evidence Reports/Technology Assessments, No. 165 ed.). Agency for Healthcare Research and Quality.
- ^ Aerbajinai, Wulin; Zhu, Jianqiong; Kumkhaek, Chutima; Chin, Kyung; Rodgers, Griffin (July 2, 2009). "CF induces γ-globin gene expression by regulating downstream transcription factor COUP-TFII". Blood. 114 (1): 187–194. doi:10.1182/blood-2008-07-170712. PMC 2927201. PMID 19401563.
- ^ a b Cui, Shuaiying; Tanabe, Osamu; Sierant, Michael; Shi, Lihong; Campbell, Andrew; Lim, Kim-Chew; Engel, James (26 February 2015). "Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes". Blood. 125 (9): 1477–1487. doi:10.1182/blood-2014-10-605022. PMC 4342359. PMID 25561507.
- ^ "Griffin P. Rodgers".